Navafenterol
Product Specifications
UNSPSC Description
Navafenterol?(AZD-8871)?is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3?receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD).?Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile[1].
Target Antigen
Adrenergic Receptor; mAChR
Type
Reference compound
Related Pathways
GPCR/G Protein;Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/navafenterol.html
Solubility
10 mM in DMSO
Smiles
O=C(C(O)(C1=CC=CS1)C2=CC=CS2)O[C@H]3CC[C@@H](CC3)N(C)CCCN4N=NC5=CC(CNC[C@H](O)C6=CC=C(C7=C6C=CC(N7)=O)O)=CC=C54
Molecular Weight
742.91
References & Citations
[1]Mònica Aparici, et al. Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/ β 2-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile. J Pharmacol Exp Ther. 2019 Jul;370(1):127-136.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-120802/Navafenterol-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-120802/
Clinical Information
Phase 2
CAS Number
1435519-06-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BNC741708-500 500 µL
Anti-EGFR (Epidermal Growth Factor Receptor) (GFR/1708), CF740 conjugate
Ask
View Details 